Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-IMMUNE: Atezolizumab with preoperative radio-chemotherapy in localized rectal cancer
2016-004526-41Phase 2Completed
- Sponsor
- Grand Hôpital de Charleroi
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in rectal adenocarcinoma, sponsored by Grand Hôpital de Charleroi. Primary endpoints: Safety and tolerability (phase Ib and II) and Efficacy of atezolizumab + preoperative radio-chemotherapy (phase Ib and II overall objective). Started Nov 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on 2016-004526-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004526-41.